Fears Of Too Many OTC Choices Should Not Restrict Switches, Stakeholders Say
This article was originally published in The Tan Sheet
FDA and its advisory committees should not meddle with the free market by potentially limiting Rx-to-OTC switches based on how crowded a self-care category is or by removing “obsolete” ingredients from the market once new, improved treatments become available, stakeholders argue.
You may also be interested in...
FDA approved Merck’s overactive bladder drug Oxytrol for Women for OTC use, despite concerns raised by the Nonprescription Drug Advisory Committee in November. The company plans a launch in the fall.
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.